Immunotherapy in gynecological cancers

Immunotherapy has changed the natural history of several malignancies that, a decade ago, had a very poor prognosis, such as lung cancer and melanoma. Consequently, many attempts have been done to expand the indications of immunotherapy agents, predominantly immune checkpoint inhibitors (ICIs), in o...

Full description

Saved in:
Bibliographic Details
Published inExploration of targeted anti-tumor therapy Vol. 2; no. 1; pp. 48 - 64
Main Authors Lorusso, Domenica, Ceni, Valentina, Daniele, Gennaro, Pietragalla, Antonella, Salutari, Vanda, Muratore, Margherita, Nero, Camilla, Ciccarone, Francesca, Scambia, Giovanni
Format Journal Article
LanguageEnglish
Published Open Exploration 01.01.2021
Open Exploration Publishing Inc
Subjects
cervical cancer
endometrial cancer
immunotherapy
ovarian cancer
Review
Online AccessGet full text

Cover

More Information
Summary:Immunotherapy has changed the natural history of several malignancies that, a decade ago, had a very poor prognosis, such as lung cancer and melanoma. Consequently, many attempts have been done to expand the indications of immunotherapy agents, predominantly immune checkpoint inhibitors (ICIs), in other cancers, including gynecological malignancies. Alongside promising results in cervical and endometrial neoplasms, there are not clear data on the benefit of ICIs as single agent or in combination with antiangiogenic agents in ovarian cancer (OC) and ongoing trials are focusing on combining ICIs with standard chemotherapy or PARP inhibitors. This chapter summarized the evidences of ICIs in gynecological malignancies and report the ongoing trials in cervical, endometrial and OC.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2692-3114
2692-3114
DOI:10.37349/etat.2021.00033